Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech product update

MDCE Melanoma Scan Beta Volunteer Dataset Review

Analysis based on 23 articles · First reported Aug 31, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
1
Articles
23
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcements represent incremental development progress for a micro-cap OTC-listed company and are unlikely to materially move broader markets. Any market impact would be confined to speculative interest in Medical Care Technologies Inc. shares, with limited liquidity and no near-term revenue implications given the beta-stage, non-cleared status of the product.

healthcare technology artificial intelligence medical imaging

Medical Care Technologies Inc. (OTCID:MDCE) announced a series of milestones in the development of its MDCE Melanoma Scan Beta platform, an AI-assisted imaging and body-map monitoring application. On August 31, 2026, the company announced it was seeking its first volunteers for human-submitted dataset testing, moving beyond training solely on public cancer imaging archives such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. On September 4, 2026, the company confirmed that volunteer intake was active for the first human-submitted image cohort. On September 16, 2026, Medical Care Technologies Inc. announced it had received its first human volunteer image datasets, which entered internal review. On September 23, 2026, the company announced that internal review of those first volunteer-submitted image datasets was underway, focusing on image intake, body-map mapping, and change-over-time comparison. CEO Marshall Perkins characterized the receipt and review of volunteer data as major milestones. The platform remains in beta-stage development, has not received regulatory clearance, and is not intended to diagnose, treat, cure, or prevent any disease or medical condition.

75 Medical Care Technologies Inc. announced public beta preview
65 Medical Care Technologies Inc. received volunteer image datasets
50 Medical Care Technologies Inc. activated volunteer intake
priv
The company is the sole actor in this event, announcing receipt and internal review of first volunteer image datasets for its MDCE Melanoma Scan Beta platform. The progress is a positive development milestone but remains pre-revenue and without regulatory clearance.
Importance 100.0 Sentiment 10.0
per
As CEO of Medical Care Technologies Inc., Marshall Perkins is the public voice of the announcements, framing the volunteer dataset receipt and review as major milestones for the Melanoma Scan Beta testing program.
Importance 30.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.